Alba Gabarroca Garcia

Alba Gabarroca Garcia

Auto-generated profile, based on publicly available information

Alba Gabarroca Garcia

Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MCMaría Ríos Carrasco
María Ríos Carrasco
TLTing-Hui Lin
Ting-Hui Lin
XZXueyong Zhu
Xueyong Zhu
AGAlba Gabarroca García
Alba Gabarroca García
EUElif Uslu
Elif Uslu
RVRobert P. De Vries
Robert P. De Vries
H5Nx viruses continue to wreak havoc in avian and mammalian species worldwide. The virus distinguishes itself by the ability to replicate to high titers and transmit efficiently in a wide variety of hosts in diverse climatic environments. Fortunately, transmission to and between humans is scarce. Yet, if such an event were to occur, it could spark a pandemic as humans are immunologically naïve to H5 viruses. A significant determinant of transmission to and between humans is the ability of the influenza A virus hemagglutinin (HA) protein to shift from an avian-type to a human-type receptor specificity. Here, we demonstrate that a 2016 2.3.4.4e virus HA can convert to human-type receptor binding via a single Q226L mutation, in contrast to a cleavage-modified 2016 2.3.4.4b virus HA. Using glycan arrays, X-ray structural analyses, tissue- and direct glycan binding, we show that L133a Δ and 227Q are vital for this phenotype. Thus, whereas the 2.3.4.4e virus HA only needs a single amino acid mutation, the modified 2016 2.3.4.4b HA was not easily converted to human-type receptor specificity.

28 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
RHRemi Hatinguais
Remi Hatinguais
AGAlba Gabarroca Garcia
Alba Gabarroca Garcia
AAAmouretty Agard
Amouretty Agard
VLVictor Lorrain
Victor Lorrain
PHPriscilla D.A.M. Heijnen
Priscilla D.A.M. Heijnen
Sandra J. Van VlietSandra J. Van Vliet
Sandra J. Van Vliet
Production of aberrant glycans by cancer cells constitutes a key immunosuppressive strategy to avoid destruction by immune cells. Although sialic acid-containing glycans are known to dampen the activation of lymphocytes, including Natural Killer (NK) cells, the role of fucose-containing glycans remains poorly characterized. In this work, we explored the role of Lewis X (LeX) in cancer cell-NK cell interactions. We induced ectopic expression of FUT9 , an α1-3/4-fucosyltransferase, in two colorectal cancer cell lines and showed this enzyme only synthesized LeX structures but not sialyl-LeX. FUT9 introduction was not associated with altered MHC class I surface expression, nor with CD2 (which has been proposed as a receptor for LeX) binding to cancer cells. By inhibiting fucosylation we could demonstrate that CD2 binding was furthermore independent of surface fucosylated glycans in three independent cell lines. Lastly, FUT9/LeX had a limited role in cancer cell destruction and expression of activation markers by NK cells. Overall, our study suggests that, unlike sialylated glycans, α1-3/4-fucosylated glycans have limited impact on cancer cell evasion of NK cell-mediated destruction.